Drug intelligence / Profile preview

KQB168

Development stage: Phase 1
Lead developer: Kumquat Biosciences
Modality: Small Molecules

Overview

KQB168 is an investigational drug being developed for the treatment of advanced solid tumor malignancies in adults. The specific mechanism of action has not been publicly disclosed, but it is being studied both as monotherapy and in combination with pembrolizumab (Keytruda), a PD-1 inhibitor. The drug is part of Kumquat Biosciences' pipeline, which focuses on combining novel targeted therapies with immuno-oncology approaches to address cancer resistance and relapse[1][3][5]. KQB168 is notable for its development partnership between Kumquat Biosciences and Takeda, reflecting significant industry interest[5].

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on KQB168.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQB168.

Explore the full profile